Nuvo inflammation news

Nuvo said it received €4.4 million ($5.3 million) in funding from the Development Bank of Saxony (SAB) in Germany. The funding will cover development expenses for a reformulated version of WF10, including CMC activities and preclinical studies. In 2009, Nuvo partnered with the Fraunhofer Institute for Cell Therapy and Immunology IZI (Leipzig, Germany) to co-develop WF10 for allergic rhinitis and rheumatoid arthritis. In 2009, the SAB committed to provide financial support for three years. ...